Skip to content
Back to meeting Original
Stephen V Liu, MD· @StephenVLiu · X·· 1 day agoScore70
Body · original

After expertly delivered #ESMO26 plenary, phase III Krascendo 1 study from Dr. @FSkoulidis now @NEJM. Divarasib superior with PFS 9.8m vs 5.7m (HR 0.58) and OS 17.7m vs 12m (HR 0.56). RR 58% vs 32% and DOR 11.9m vs 6.9m. G3-4 TRAEs 25% vs 35%.

https://www.nejm.org/doi/full/10.1056/NEJMoa2605703

233 views · 11 likes · 4 reposts · 0 replies

Conference abstracts

Source: Stephen V Liu, MD · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.